{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:33:46Z","timestamp":1767998026382,"version":"3.49.0"},"reference-count":56,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myelofibrosis is one of the classical Philadelphia chromosome\u2013negative myeloproliferative neoplasms characterized by progressive marrow failure and chronic inflammation. Discovery of the JAK2 mutation paved the way for development of small molecular inhibitors and further facilitated the research in understanding of molecular biology of the disease. Development of novel medications and synergistic combinations with standard JAK inhibitor (JAKi) therapy may have the potential to improve depth and duration of disease control and symptomatic benefit, whereas advancements in allogeneic hematopoietic stem cell transplantation (HCT) have improved tolerability and donor availability, allowing for more patients to pursue this potentially curative therapy. The increase in options for medical therapy and changing risk profile of HCT is leading to increased complexity in counseling patients on choice of management strategy. In this case-based review, we summarize our approach to symptom-directed medical therapy, including the use of novel drugs and combination therapies currently under study in advanced clinical trials. We outline our recommendations for optimal timing of HCT, including risk-adapted selection for early HCT as opposed to delayed HCT after upfront JAKi therapy, as well as the use of pretransplant JAKi and alternative donor sources.<\/jats:p>","DOI":"10.1182\/hematology.2021000279","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:15:35Z","timestamp":1639138535000},"page":"453-462","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?"],"prefix":"10.1182","volume":"2021","author":[{"given":"James","family":"England","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"suppl 1","key":"2021121012075481700_hem2021000279C1","doi-asserted-by":"crossref","first-page":"100711","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms","volume":"42","author":"Koschmieder","year":"2020","journal-title":"Blood Rev"},{"issue":"8","key":"2021121012075481700_hem2021000279C2","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2021121012075481700_hem2021000279C3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2021121012075481700_hem2021000279C4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/13543784.2020.1751121","article-title":"Investigational non-JAK inhibitors for chronic phase myelofibrosis","volume":"29","author":"Bankar","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"2021121012075481700_hem2021000279C5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-05-399048","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors","volume":"120","author":"Gupta","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2021121012075481700_hem2021000279C6","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"2021121012075481700_hem2021000279C7","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2021121012075481700_hem2021000279C8","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10428194.2020.1845334","article-title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"2021121012075481700_hem2021000279C9","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2017009530","article-title":"Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1\/2 inhibitor therapy","volume":"1","author":"Spiegel","year":"2017","journal-title":"Blood Adv"},{"issue":"21","key":"2021121012075481700_hem2021000279C10","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012075481700_hem2021000279C11","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1016\/j.clml.2019.07.366","article-title":"Outcomes following failure of JAK1\/2 inhibitor therapy in patients with myelofibrosis is dependent on the pattern of failure","volume":"19","author":"McNamara","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"2021121012075481700_hem2021000279C12","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL- negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"2021121012075481700_hem2021000279C13","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1182\/bloodadvances.2020002621","article-title":"Comparison of outcomes of HCT in blast phase of BCR-ABL1-MPN with de novo AML and with AML following MDS","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2021121012075481700_hem2021000279C14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2021121012075481700_hem2021000279C15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021121012075481700_hem2021000279C16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"2021121012075481700_hem2021000279C17","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70\u2009+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"2021121012075481700_hem2021000279C18","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121012075481700_hem2021000279C19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/hematology.2020000088","article-title":"How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia","volume":"2020","author":"Walker","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2021121012075481700_hem2021000279C20","doi-asserted-by":"crossref","first-page":"600.e1","DOI":"10.1016\/j.jtct.2021.03.027","article-title":"Association of factors influencing selection of upfront hematopoietic cell transplantation versus non-transplant therapies in myelofibrosis: transplant decisions in MF","volume":"27","author":"Smith","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2021121012075481700_hem2021000279C21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"issue":"3","key":"2021121012075481700_hem2021000279C22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1365-2141.1998.00833.x","article-title":"Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups","volume":"102","author":"Cervantes","year":"1998","journal-title":"Br J Haematol"},{"issue":"13","key":"2021121012075481700_hem2021000279C23","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2021121012075481700_hem2021000279C24","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2021121012075481700_hem2021000279C25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.hoc.2020.12.004","article-title":"Application of stem cell therapy in myelofibrosis","volume":"35","author":"Davidson","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"2021121012075481700_hem2021000279C26","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"issue":"9","key":"2021121012075481700_hem2021000279C27","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2021121012075481700_hem2021000279C28","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2021121012075481700_hem2021000279C29","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv"},{"key":"2021121012075481700_hem2021000279C30","article-title":"Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms (MPN) [published online 4 May 2021]","author":"Marcault","journal-title":"Blood"},{"issue":"20","key":"2021121012075481700_hem2021000279C31","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2021121012075481700_hem2021000279C32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2021121012075481700_hem2021000279C33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2021121012075481700_hem2021000279C34","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2021121012075481700_hem2021000279C35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2021121012075481700_hem2021000279C36","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2021121012075481700_hem2021000279C37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2018-99-110785","article-title":"Ruxopeg, a multi-center Bayesian phase 1\/2 adaptive randomized trial of the combination of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasm (MPN)\u2013associated myelofibrosis","volume":"132","author":"Kiladjian","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012075481700_hem2021000279C38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.HS9.0000561592.51072.9b","article-title":"S828: a randomized, double blind phase 2 study of 3 different doses of PRM-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib","volume":"3","author":"Verstovsek","year":"2019","journal-title":"HemaSphere"},{"issue":"9","key":"2021121012075481700_hem2021000279C39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2021121012075481700_hem2021000279C40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"7","key":"2021121012075481700_hem2021000279C41","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/13696998.2020.1741381","article-title":"Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis","volume":"23","author":"Mascarenhas","year":"2020","journal-title":"J Med Econ"},{"issue":"6","key":"2021121012075481700_hem2021000279C42","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"2021121012075481700_hem2021000279C43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1200\/JOP.19.00506","article-title":"Patterns of ruxolitinib therapy failure and its management in myelofibrosis: perspectives of the Canadian Myeloproliferative Neoplasm Group","volume":"16","author":"Gupta","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"2021121012075481700_hem2021000279C44","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.clml.2020.04.015","article-title":"Splenectomy in myelofibrosis: indications, efficacy, and complications","volume":"20","author":"Malato","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2021121012075481700_hem2021000279C45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","article-title":"Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"2021121012075481700_hem2021000279C46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41409-021-01252-7","article-title":"Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups","volume":"56","author":"Robin","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2021121012075481700_hem2021000279C47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbmt.2018.09.001","article-title":"Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: myeloproliferative disorders research Consortium 114 study","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2021121012075481700_hem2021000279C48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41409-019-0523-3","article-title":"Pre-hematopoietic cell transplant ruxolitinib in patients with primary and secondary myelofibrosis","volume":"55","author":"Salit","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2021121012075481700_hem2021000279C49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ejh.13099","article-title":"Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"101","author":"Shahnaz Syed Abd Kadir","year":"2018","journal-title":"Eur J Haematol"},{"issue":"3","key":"2021121012075481700_hem2021000279C50","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase \u00bd inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2021121012075481700_hem2021000279C51","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2021121012075481700_hem2021000279C52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2021121012075481700_hem2021000279C53","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bbmt.2015.09.028","article-title":"Improved outcome of alternative donor transplantations in patients with myelofibrosis: from unrelated to haploidentical family donors","volume":"22","author":"Bregante","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2021121012075481700_hem2021000279C54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136622","article-title":"Haploidentical allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide in patients with myelofibrosis: a multi-institutional experience","volume":"136","author":"Kunte","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2021121012075481700_hem2021000279C55","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbmt.2018.10.017","article-title":"Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation","volume":"25","author":"Raj","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2021121012075481700_hem2021000279C56","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.bbmt.2019.02.019","article-title":"Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups","volume":"25","author":"Murata","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/453\/1851800\/453england.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/453\/1851800\/453england.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:16:37Z","timestamp":1639138597000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/453\/482995\/Novel-therapies-vs-hematopoietic-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000279","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}